Annexin-1 Binding Molecules for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T cell-mediated diseases, such as autoimmune disorders, are inadequate as they fail to effectively modulate the adaptive immune response, particularly the role of Annexin-1 (Anx-A1) in T cell activation and differentiation, leading to aberrant immune responses.
Innovation Solution
Development of specific binding molecules that target and bind to Annexin-1 (Anx-A1) to block its activity, thereby modulating T cell receptor signaling and skewing the differentiation of T cells towards a less inflammatory Th2 response, thereby treating T cell-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat autoimmune diseases, then both innate and adaptive immune responses are blocked, but the mechanism by which they modulate adaptive immunity (through Annexin-1) has been neglected and not fully utilized for therapeutic benefit
Solution Approach 1:
The patent identifies Annexin-1 as the intermediary molecule that mediates glucocorticoid effects on adaptive immunity. By targeting this specific mediator with binding molecules, the invention enables precise control over T cell activation and differentiation, resolving the contradiction by transforming neglected information into therapeutic opportunity
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific glucocorticoid administration to specific binding molecules that modulate Annexin-1 activity. This parameter change allows selective modulation of adaptive immunity without the broad suppressive effects of traditional GC therapy
2Productivity
If Annexin-1 levels are increased in T cells, then T cell activation threshold is lowered and Th1 differentiation is favoured, but this leads to aberrant immune responses in autoimmune diseases
Solution Approach 1:
The patent applies preliminary anti-action by using binding molecules to block Annexin-1 activity before it can cause aberrant T cell activation. This preventive approach stops the harmful effect at its source while preserving normal T cell function
Solution Approach 2:
The invention converts the harmful high Annexin-1 levels that cause aberrant immunity into a beneficial target for therapy. By designing binding molecules against Annexin-1, the harmful protein becomes the focus of therapeutic intervention, transforming the problem into a solution
3Reliability
If specific binding molecules targeting Annexin-1 are developed, then T cell activation is reduced and Th2 differentiation is skewed, but the complexity of developing and administering these molecules increases
Solution Approach 1:
The patent extracts the critical function of Annexin-1 from the complex immune system and isolates it as a specific target. By focusing therapy on this single molecule rather than the entire immune system, the invention simplifies the therapeutic approach while maintaining effectiveness
Solution Approach 2:
The binding molecules against Annexin-1 serve multiple functions: they block T cell activation, prevent Th1 differentiation, and treat various autoimmune diseases. This multi-functionality justifies the development complexity by providing broad therapeutic benefit from a single target
Data Source
AI summary
The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease.